These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21764127)

  • 1. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
    Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
    Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
    [No Abstract]   [Full Text] [Related]  

  • 3. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
    Jädersten M; Karsan A
    Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
    [No Abstract]   [Full Text] [Related]  

  • 5. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 8. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 10. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
    Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
    Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The 5q- syndrome].
    Adès L; Fenaux P
    Rev Prat; 2010 Dec; 60(10):1420-2. PubMed ID: 21425544
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
    Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
    [No Abstract]   [Full Text] [Related]  

  • 19. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.